Fitting Zanubrutinib into the Treatment Landscape for Mantle Cell Lymphoma
September 27th 2019Michael Wang, MD, discusses the potential role for the next-generation Bruton's tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.